Sana Biotechnology Inc (SANA) 뉴스

Form 8-K - Current report

Sana Biotechnology to Present at September 2024 Investor Conferences

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated...

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner PR Newswire CAMBRIDGE, Mass., Aug...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glia

Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated...